These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18986239)

  • 1. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
    Linker RA; Lee DH; Stangel M; Gold R
    Expert Rev Neurother; 2008 Nov; 8(11):1683-90. PubMed ID: 18986239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethyl fumarate for multiple sclerosis.
    Papadopoulou A; D'Souza M; Kappos L; Yaldizli O
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1603-12. PubMed ID: 21067468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on fumarates.
    Lee DH; Linker RA; Gold R
    Int MS J; 2008 Mar; 15(1):12-8. PubMed ID: 18713564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action.
    Gold R; Linker RA; Stangel M
    Clin Immunol; 2012 Jan; 142(1):44-8. PubMed ID: 21414846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects].
    Stangel M; Moharregh-Khiabani D; Linker RA; Gold R
    Nervenarzt; 2008 Feb; 79(2):212-7. PubMed ID: 18210050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of action and clinical studies with fumarates in multiple sclerosis.
    Salmen A; Gold R
    Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copolymer-1.
    Comi G; Moiola L
    Baillieres Clin Neurol; 1997 Oct; 6(3):495-509. PubMed ID: 10101586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BG-12 in multiple sclerosis.
    Phillips JT; Fox RJ
    Semin Neurol; 2013 Feb; 33(1):56-65. PubMed ID: 23709213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fumaric acid esters in psoriasis and multiple sclerosis.
    Zecca C; Caporro M; Adami M; Mainetti C; Gobbi C
    Clin Exp Dermatol; 2014 Jun; 39(4):488-91. PubMed ID: 24779791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate.
    Wakkee M; Thio HB
    Curr Opin Investig Drugs; 2007 Nov; 8(11):955-62. PubMed ID: 17979030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinuria with fumaric acid ester treatment for psoriasis.
    Ogilvie S; Lewis Jones S; Dawe R; Foerster J
    Clin Exp Dermatol; 2011 Aug; 36(6):632-4. PubMed ID: 21771009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and development of new therapeutics for multiple sclerosis.
    Linker RA; Kieseier BC; Gold R
    Trends Pharmacol Sci; 2008 Nov; 29(11):558-65. PubMed ID: 18804288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
    Schimrigk S; Brune N; Hellwig K; Lukas C; Bellenberg B; Rieks M; Hoffmann V; Pöhlau D; Przuntek H
    Eur J Neurol; 2006 Jun; 13(6):604-10. PubMed ID: 16796584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA; Kim E; Moodie J
    Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Bonzano L; Roccatagliata L; Mancardi GL; Sormani MP
    Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters.
    Lee DH; Gold R; Linker RA
    Int J Mol Sci; 2012; 13(9):11783-11803. PubMed ID: 23109883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.